HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
2,980.00
-80.00 (-2.61%)
Oct 10, 2025, 3:30 PM KST
HLB Therapeutics Revenue
HLB Therapeutics had revenue of 15.67B KRW in the quarter ending June 30, 2025, with 34.38% growth. This brings the company's revenue in the last twelve months to 61.23B, up 3.54% year-over-year. In the year 2024, HLB Therapeutics had annual revenue of 54.93B with 4.45% growth.
Revenue (ttm)
61.23B
Revenue Growth
+3.54%
P/S Ratio
4.09
Revenue / Employee
1.25B
Employees
49
Market Cap
250.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
Dec 31, 2020 | 42.93B | -16.04B | -27.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |